yahoo_financeOriginal article
Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
Data ReadoutpositiveWegovyPositive
AI Analysis
Summary
Novo Nordisk announced that Wegovy (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat, based on data presented at EASD 2026.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat
Importance:6/10
Sentiment:
0.80
obesityliver healthsemaglutideEASD conferenceclinical data
Related Companies
Read the original article
Published by yahoo_finance on October 1, 2026 10:45 AM